Nuvation Bio (NUVB)
(Delayed Data from NYSE)
$2.91 USD
+0.11 (3.93%)
Updated Jun 6, 2024 04:00 PM ET
After-Market: $2.90 -0.01 (-0.34%) 6:12 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NUVB 2.91 +0.11(3.93%)
Will NUVB be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for NUVB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NUVB
Nuvation Bio Inc. (NUVB) Is Up 25.28% in One Week: What You Should Know
Nuvation Bio Inc. (NUVB) Upgraded to Buy: What Does It Mean for the Stock?
NUVB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for NUVB
TD Cowen Sticks to Its Buy Rating for Nuvation Bio (NUVB)
Buy Rating for Nuvation Bio on Taletrectinib’s Promising NSCLC Treatment Efficacy and Favorable Financial Outlook
Buy Rating for Nuvation Bio: Taletrectinib’s Promising Efficacy and Strategic Path to Approval
Nuvation Bio announces data from pivotal Phase 2 TRUST-I study
Innovent Announces Taletrectinib(ROS1 Inhibitor)Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting